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Understanding the molecular 
mechanisms of chemoresistance is vital 
to design therapies to restore 
chemosensitivity.  In particular, 
metadherin (MTDH) has been 
demonstrated to have a critical role in 
chemoresistance.  Over-expression of 
MTDH has recently been correlated with 
poor clinical outcomes in breast cancer, 
neuroblastoma, hepatocellular 
carcinoma and prostate cancer. In 
endometrial cancer patients, lymph 
node metastasis and increase of 
mortality were significantly associated 
with chromosome 8q22-q23copy 
number gains, which is where MTDH is 
localized. However, it is unclear how 
MTDH overexpression mechanistically 
contributes to endometrial cancer 
development, progression, or response 
to therapy. In this present study, we 
detected overexpression of MTDH in 
endometrial cancer tissues compared to 
normal endometrium. Studies in 
endometrial cancer cell lines indicate 
that MTDH depletion enhanced 
sensitivity to chemotherapy agents as 
well as cell death induced by a 
combinatorial treatment of histone 
deacetylase (HDAC) inhibitor and tumor 
necrosis factor-alpha-related apoptosis-
inducing ligand (TRAIL) .  TRAIL 
promotes death of cancerous cells of 
the human reproductive tract, and 
HDAC inhibitors, such as LBH 589 used 
in this study, have been shown to 
increase sensitivity of cancer cells to 
TRAIL-induced apoptosis. Inhibition of 
PI3K/AKT survival pathway such as 
PDK1 and AKT phosphorylation, 
increased degradation of anti-apoptosis 
protein XIAP, and increased expression 
of pro-apoptosis protein Bim and 
cleaved active isoforms of caspase 8 
and caspase 3 were all  observed during 
cell death induced by TRAIL and LBH 
589 combination treatment in MTDH 
depleted endometrial cancer cells. 
However, in cancer cells with MTDH 
overexpression, TRAIL/LBH 589 
treatment had no effect on these pro-
survival factors. Interestingly, MTDH 
was also found to be involved in G2/M 
checkpoint regulation. Treatment of 
MTDH-depleted cells with TRAIL and 
LBH589 resulted in an increased 
number of cells arrested in G2/M 
compared to cells with MTDH 
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overexpression. Using microarray 
technology, 57 genes with greater than 
two-fold gene expression alteration were 
identified after MTDH depletion, 
including Calbindin 1 and Galectin 1, 
which may contribute to MTDH-
mediated drug resistance. Therefore, 
MTDH mediates drug resistance by 
regulating expression of genes required 
for the control of apoptosis and cell 
cycle. These findings indicate that 
sensitivity to chemotherapy agents and 
combination treatment with HDAC 
inhibitor and TRAIL can be restored by 
manipulating MTDH, and hence 
depletion of MTDH is a potentially novel 
avenue for effective cancer therapy.  
 
